Last updated: August 1, 2026
Hydralazine hydrochloride plus hydrochlorothiazide is an established, low-cost antihypertensive combination with no meaningful remaining composition-of-matter exclusivity. Current clinical development is limited, and the commercial opportunity is concentrated in generic, hospital, and niche hypertension channels. The combination has limited differentiation against modern fixed-dose products containing an angiotensin receptor blocker, calcium-channel blocker, or thiazide-type diuretic.
What is the clinical status of hydralazine hydrochloride and hydrochlorothiazide?
Hydralazine is a direct arteriolar vasodilator. Hydrochlorothiazide is a thiazide diuretic. Their pharmacology is complementary: hydrochlorothiazide reduces sodium and plasma volume, while hydralazine lowers systemic vascular resistance.
The combination was historically used for hypertension, but hydralazine is now generally reserved for selected patients because of tachycardia, fluid retention, frequent dosing, and immune-mediated adverse effects. Current clinical use is more common in severe hypertension, pregnancy-related hypertension, heart failure protocols, and patients unable to tolerate preferred first-line drugs.
| Attribute |
Hydralazine hydrochloride |
Hydrochlorothiazide |
| Drug class |
Direct vasodilator |
Thiazide diuretic |
| Primary effect |
Reduces arteriolar resistance |
Increases urinary sodium and water excretion |
| Typical role |
Resistant or severe hypertension; selected heart failure use |
First-line hypertension and edema therapy |
| Key limitations |
Reflex tachycardia, lupus-like syndrome, fluid retention |
Hyponatremia, hypokalemia, hyperuricemia, photosensitivity |
| Regulatory status |
Approved generic active ingredient |
Approved generic active ingredient |
| Development status |
No major new-drug program identified |
No major new-drug program identified |
The combination does not have the clinical development profile of a new molecular entity. It has no current evidence base suggesting a large late-stage trial program, new indication strategy, or active specialty-pharma development platform.
Are there active clinical trials for the combination?
No major late-stage clinical-trial program is associated with the fixed combination of hydralazine hydrochloride and hydrochlorothiazide. ClinicalTrials.gov contains studies involving hydralazine or hydrochlorothiazide individually, but these are generally investigator-led or focused on different clinical questions rather than registration trials for the fixed-dose combination.
What clinical research remains relevant?
Current research involving the component drugs is more likely to address:
- Acute blood-pressure control in hospital settings
- Hypertension during pregnancy
- Heart failure treatment involving hydralazine with isosorbide dinitrate
- Renal and cardiovascular outcomes associated with thiazide therapy
- Comparative safety of thiazide and thiazide-like diuretics
- Pharmacogenomics and adverse-event risk associated with hydralazine
The most commercially relevant clinical evidence does not support a new product cycle for hydralazine/hydrochlorothiazide. Modern hypertension guidelines place thiazide-type diuretics among preferred agents, but hydralazine is not generally recommended as an initial treatment option because of tolerability and dosing limitations (U.S. Department of Veterans Affairs and U.S. Department of Defense, 2020; Whelton et al., 2018).
What is the FDA regulatory status of hydralazine hydrochloride and hydrochlorothiazide?
Both active ingredients are FDA-approved and marketed in multiple generic dosage forms. The fixed-dose combination has historical regulatory precedent, but commercial availability depends on the specific manufacturer, strength, and national market.
Hydralazine hydrochloride tablets are approved for hypertension. Hydrochlorothiazide tablets are approved for hypertension and edema. The combination historically appeared in products such as Apresazide, although branded availability has declined and generic supply is limited relative to single-agent products.
Is the combination an FDA-approved fixed-dose product?
Historical fixed-dose products have been approved or marketed, but the commercial status of a specific hydralazine/hydrochlorothiazide product must be evaluated by National Drug Code, manufacturer, and current FDA listing. The active ingredients themselves remain established generic products.
The regulatory value is therefore primarily manufacturing and distribution-based. It is not based on a new chemical entity, novel mechanism, or active exclusivity period.
What is the Orange Book status of hydralazine hydrochloride and hydrochlorothiazide?
Hydralazine and hydrochlorothiazide have no remaining meaningful composition-of-matter patent protection. Any applicable fixed-combination listings, formulation claims, or method-of-use claims would need to be assessed at the individual product level in the FDA Orange Book.
For a generic applicant, the key questions are:
- Whether the reference product remains listed as approved and active.
- Whether the product has an approved reference listed drug.
- Whether any patents or regulatory exclusivity are listed against that reference product.
- Whether the proposed strength and dosage form match the reference product.
- Whether a suitability petition, abbreviated new drug application, or other regulatory route is required.
Because these ingredients are old and widely used, the principal barriers are unlikely to be patent barriers. They are more likely to involve formulation equivalence, product availability, manufacturing economics, and commercial scale.
When does hydralazine hydrochloride and hydrochlorothiazide lose exclusivity?
The combination has effectively lost market exclusivity. Hydralazine was approved decades ago, and hydrochlorothiazide has been marketed for many decades. Any original patent term and FDA exclusivity period have expired.
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Composition-of-matter patent |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
Not relevant to the legacy combination |
| New clinical investigation exclusivity |
No current qualifying program identified |
| Biosimilar exclusivity |
Not applicable |
| Generic competition |
Legally permitted, subject to product-specific approval requirements |
There is no credible basis for a new exclusivity period unless a manufacturer develops and obtains approval for a distinct product with qualifying clinical, formulation, or delivery-system claims.
What patents protect hydralazine hydrochloride and hydrochlorothiazide?
No commercially important active-ingredient patent estate remains for either component. Legacy patents covering hydralazine, hydrochlorothiazide, or their basic combination are expired.
Potentially relevant intellectual-property categories include:
- Tablet composition and excipient systems
- Modified-release delivery
- Taste masking or dispersible dosage forms
- Combination products with a third active ingredient
- Manufacturing processes
- Packaging and stability systems
- Digital adherence or titration services linked to a branded product
These categories would protect a newly developed product only if the claims were novel, non-obvious, enabled, and commercially relevant. A conventional immediate-release tablet containing hydralazine hydrochloride and hydrochlorothiazide would face a weak patent position.
How strong is the patent estate?
The patent estate is weak for a conventional fixed-dose tablet and stronger only for a genuinely differentiated formulation. Even then, formulation patents would face validity and design-around risks because both active ingredients have extensive prior art.
| IP category |
Estimated commercial strength |
| Active-ingredient patents |
None of practical value |
| Conventional fixed-dose tablet |
Weak |
| New-release profile |
Moderate if clinically meaningful |
| Manufacturing process |
Low to moderate |
| Combination with novel third agent |
Product-specific |
| Device-enabled delivery |
Potentially moderate, but limited market fit |
What is the current market for hydralazine hydrochloride and hydrochlorothiazide?
The market is generic and fragmented. Public company reports generally do not disclose revenue for this specific combination because sales are included within broader generic cardiovascular portfolios.
Demand is constrained by clinical substitution. Physicians commonly use hydrochlorothiazide with losartan, valsartan, lisinopril, amlodipine, or other standard agents. Hydralazine is more often prescribed as a separate tablet, frequently with a beta blocker or nitrate, rather than in a hydralazine/hydrochlorothiazide fixed-dose product.
Main market segments
| Segment |
Commercial relevance |
| Retail generic hypertension |
Low |
| Hospital formularies |
Moderate for hydralazine monotherapy |
| Pregnancy-related hypertension |
Limited but clinically relevant |
| Heart failure |
Hydralazine is used mainly with isosorbide dinitrate |
| Long-term resistant hypertension |
Niche |
| Emerging markets |
Potentially higher because of low price and established supply chains |
| Specialty branded market |
Minimal |
The product can retain a small but durable market where prescribers value familiarity, low acquisition cost, and availability. The combination is unlikely to generate material branded revenue without a new delivery system, adherence benefit, or clinical positioning.
What is the 2025-2030 market projection?
A precise global revenue forecast is not supportable because the combination is not consistently reported as a separate market category. A scenario framework is more appropriate.
| Scenario |
2025-2030 unit trend |
Revenue trend |
Main assumptions |
| Base case |
Flat to declining |
Declining low-single digits annually |
Continued generic substitution and limited clinical adoption |
| Downside |
Declining mid-single digits |
Declining mid- to high-single digits |
Product discontinuations and migration to newer combinations |
| Upside |
Low-single-digit growth |
Flat to low-single-digit growth |
Supply improvements, emerging-market demand, or hospital formulary expansion |
The broader hypertension market will grow through population aging, diagnosis, and treatment expansion. Hydralazine/hydrochlorothiazide is unlikely to capture that growth because it lacks the guideline preference and commercial infrastructure of newer fixed-dose combinations.
A manufacturer could achieve modest returns through contract manufacturing or underserved-market supply, but a large branded investment would face weak pricing power and limited prescription growth.
Which companies are likely to compete in this market?
Competition is primarily from generic manufacturers and distributors rather than research-based pharmaceutical companies. Potential competitors include companies with established generic tablet manufacturing and cardiovascular portfolios, including Teva Pharmaceutical Industries, Viatris, Dr. Reddy's Laboratories, Sandoz, Sun Pharmaceutical Industries, and regional manufacturers.
The relevant competitive variables are:
- FDA-approved product status
- Consistent supply of both active ingredients
- Low-cost tablet production
- Wholesaler and pharmacy distribution
- Ability to maintain multiple strengths
- Compliance with current good manufacturing practice requirements
- Reliable bioequivalence and stability data
The product does not present a meaningful biosimilar threat. Neither hydralazine nor hydrochlorothiazide is a biologic. Competitive risk comes from generic substitution and therapeutic substitution, not biosimilar entry.
What generic entry risks exist?
Legal generic entry risk is high because exclusivity has expired. Commercial generic entry risk is more nuanced. A new entrant may obtain approval but still struggle to build a profitable business because the market is small and price-sensitive.
Key generic risks
- Low average selling prices
- Limited pharmacy stocking
- Sparse prescribing
- Reference-product discontinuation risk
- Small addressable patient population
- Manufacturing complexity relative to expected volume
- Competition from separate-component prescriptions
- Potential difficulty demonstrating commercial demand
A generic launch could succeed if the entrant fills a supply gap, offers a discontinued strength, or supplies institutional buyers. It would be less attractive as a broad retail launch.
What patent litigation and Paragraph IV challenges affect the product?
No major current patent-litigation pattern is associated with the legacy hydralazine/hydrochlorothiazide combination. Paragraph IV litigation is generally unlikely for an old, unprotected product unless a sponsor introduces a new formulation, delivery profile, or branded combination.
A future Paragraph IV dispute would most likely concern:
- A newly approved modified-release product
- A novel fixed-dose combination
- A formulation with a proprietary excipient system
- A method-of-use claim for a narrowly defined patient population
- A patent covering a manufacturing process
For the conventional immediate-release combination, the principal risk is regulatory and commercial rather than patent litigation.
What manufacturing and IP barriers affect supply?
Manufacturing barriers are moderate. Hydralazine and hydrochlorothiazide are established small-molecule APIs, and neither requires biologic manufacturing, complex sterile processing, or cold-chain logistics.
The main operational risks are:
- API supplier qualification
- Stability and impurity control
- Tablet uniformity at low-dose strengths
- Packaging and moisture protection
- Batch-size economics
- Quality-system compliance
- Maintaining multiple strengths with low demand
Manufacturing know-how may offer limited practical protection, but it is unlikely to create durable market exclusivity. A reliable supplier can compete without owning a meaningful patent estate.
How does this combination compare with modern antihypertensive combinations?
| Product type |
Guideline position |
Adherence profile |
Commercial outlook |
| Hydralazine/HCTZ |
Limited or specialist use |
Weak because hydralazine often requires multiple daily doses |
Niche generic |
| ARB/HCTZ |
Established |
Better with once-daily dosing |
Large generic market |
| ACE inhibitor/HCTZ |
Established |
Usually once daily |
Large generic market |
| Calcium-channel blocker/ARB |
Established |
Stronger fixed-dose adherence profile |
Large and competitive |
| Chlorthalidone-based therapy |
Increasing clinical interest |
Variable |
Generic growth in selected markets |
| Hydralazine/isosorbide dinitrate |
Selected heart-failure population |
Complex dosing |
Specialty generic niche |
Hydralazine/hydrochlorothiazide is disadvantaged by dosing frequency, adverse-effect monitoring, and the availability of better-established fixed-dose combinations.
Key Takeaways
- Hydralazine hydrochloride and hydrochlorothiazide are legacy generic antihypertensive ingredients with expired exclusivity.
- No major current registration-trial program is associated with the conventional fixed-dose combination.
- The Orange Book and patent position are unlikely to create a meaningful barrier to generic entry.
- The commercial market is small, fragmented, and not separately disclosed by most manufacturers.
- Generic demand is likely to remain flat to declining through 2030.
- The strongest commercial opportunity is supply reliability, institutional contracting, or emerging-market distribution.
- A new branded product would need a clinically meaningful formulation, adherence, or combination advantage.
- Biosimilar risk is not relevant because both ingredients are small molecules.
- Competitive pressure comes mainly from therapeutic substitution into ARB/thiazide, ACE inhibitor/thiazide, and calcium-channel-blocker combinations.
- Patent litigation and Paragraph IV activity are unlikely for a conventional immediate-release product.
FAQs
Is hydralazine hydrochloride and hydrochlorothiazide still prescribed together?
Yes, but use is limited. Clinicians more often prescribe the components separately or use hydrochlorothiazide with an ARB, ACE inhibitor, or calcium-channel blocker.
Is hydralazine hydrochloride and hydrochlorothiazide a combination product or two separate drugs?
It can refer to a historical fixed-dose combination, but current prescribing may involve separate hydralazine and hydrochlorothiazide tablets. Product availability must be evaluated by specific strength and manufacturer.
Does hydralazine hydrochloride have biosimilars?
No. Hydralazine is a chemically synthesized small molecule, so generic-drug competition applies rather than biosimilar competition.
Could a new hydralazine/hydrochlorothiazide formulation obtain patent protection?
Possibly, but only a genuinely novel formulation, delivery system, manufacturing process, or clinical use could support meaningful patent value. A conventional immediate-release tablet would have a weak patent position.
Is hydralazine/hydrochlorothiazide attractive for pharmaceutical licensing?
It has limited licensing appeal as a conventional generic. The opportunity is stronger for a company with low-cost manufacturing, an underserved market channel, or a differentiated once-daily delivery system.
References
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Hydralazine hydrochloride prescribing information.
-
U.S. Food and Drug Administration. (2024). Hydrochlorothiazide prescribing information.
-
U.S. Department of Veterans Affairs, & U.S. Department of Defense. (2020). VA/DoD clinical practice guideline for the diagnosis and management of hypertension in the primary care setting.
-
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
-
National Library of Medicine. (2024). ClinicalTrials.gov. https://clinicaltrials.gov/
